Advancing Rapid Sepsis Detection

Building a better tomorrow

About Us

Diagnostic Ventures is proud to work with leading PhD researchers at Brigham Young University. Our rapid sepsis diagnostic technology has been in development since 2016 and can currently detect the 5 most deadly sepsis pathogens in as little as 90 minutes.

Originally funded by a $5.2M grant from the National Institute of Health, testing is being expanded to cover 90%+ of sepsis-causing pathogens and resistance genes.

This product is under development and not approved for sale. This product is not yet FDA approved.

Product

Our breakthrough sepsis test

Stage 1

Blood with bacteria

services image

Stage 2

Spin Blood

services image

Stage 3

Separate Pathogens from Interferents via Sedimentary Forces

services image

Stage 4

Slow to separate plasma from Interferents

services image
1. Zanotti-Cavazzoni S. Duration of hypotension before initiation of effective antimicrobial therapy is the critical determinant of survival in human septic shock.  Yearbook of Critical Care Medicine. 2007; 2007:187-188. doi:10.1016/s0734-3299(08)70339-3.